LOCALLY MANUFACTURED AUTOLOGOUS CD19 CHIMERIC ANTIGEN RECEPTOR-T (CAR-T) CELLS FOR PHASE II PROSPECTIVE CLINICAL TRIAL FOR RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKAEMIA IN MALAYSIA

被引：0
|
作者：
Lim, T. S. [1 ]
Nyunt, W. [1 ]
Then, K. [2 ]
Cheong, S. [2 ]
Then, K. [2 ]
Ooi, G. [2 ]
Govindasamy, V. [2 ]
Idris, M. Mohd [3 ]
Azura, S. [3 ]
Abdullah, N. [3 ]
Zakaria, M. Muhd [3 ,4 ]
Chang, A. H. [6 ]
Ithnin, A. [7 ]
Wahid, S. S. Abdul [3 ,5 ]
机构：
[1] Plutonet Sdn Bhd, Cyberjaya, Malaysia
[2] Cryocord Sdn Bhd, Cyberjaya, Malaysia
[3] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Pusat Terapi Sel PTS, Kuala Lumpur, Malaysia
[4] Prince Court Med Ctr, Kuala Lumpur, Malaysia
[5] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Dept Med, Fac Med, Kuala Lumpur, Malaysia
[6] Shanghai YaKe Biotechnol Ltd, Shanghai, Peoples R China
[7] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Dept Pathol, Kuala Lumpur, Malaysia
来源：
CYTOTHERAPY | 2023年 / 25卷 / 06期
关键词：
CAR-T therapy; CAR-T manufacturing;
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
1028
引用
收藏
页码：S225 / S226
页数：2
相关论文
共 50 条
  • [21] Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
    Cao, Jiang
    Wang, Gang
    Cheng, Hai
    Wei, Chen
    Qi, Kunming
    Sang, Wei
    Li Zhenyu
    Shi, Ming
    Li, Huizhong
    Qiao, Jianlin
    Pan, Bin
    Zhao, Jing
    Wu, Qingyun
    Zeng, Lingyu
    Niu, Mingshan
    Jing, Guangjun
    Zheng, Junnian
    Xu, Kailin
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) : 851 - 858
  • [22] Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Deng, Biping
    Chang, Alex Hongsheng
    Yang, Junfang
    Pan, Jing
    Zhang, Xian
    Lin, Yuehui
    Wu, Yanan
    Deng, Zhenling
    Lu, Peihua
    Wu, Tong
    Liu, Zhaoli
    Zhang, Yu'e
    Tong, Chunrong
    BLOOD, 2016, 128 (22)
  • [23] Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial
    Feng, Jingjing
    Hu, Yongxian
    Zhang, Mingming
    Cao, Heng
    Ke, Yini
    Xu, Huijun
    Cui, Jiazhen
    Zhang, Yanlei
    Chang, Alex Hongsheng
    Lin, Jin
    Wei, Guoqing
    Huang, He
    BLOOD, 2022, 140 : 10335 - 10336
  • [24] CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).
    Newman, Haley
    Leahy, Allison Emily Barz
    Li, Yimei
    Liu, Hongyan
    Myers, Regina M.
    DiNofia, Amanda M.
    Dolan, Joseph Gregory
    Callahan, Colleen
    Devine, Kaitlin J.
    Wray, Lisa
    June, Carl H.
    Grupp, Stephan A.
    Rheingold, Susan R.
    Maude, Shannon L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
    Maude, Shannon L.
    Barrett, David M.
    Ambrose, David E.
    Rheingold, Susan R.
    Aplenc, Richard
    Teachey, David T.
    Callahan, Colleen
    Barker, Christine S.
    Mudambi, Maya
    Shaw, Pamela A.
    Brogdon, Jennifer
    Young, Regina M.
    Scholler, John
    Loew, Andreas
    Marcucci, Katherine T.
    Finklestein, Jeffrey
    Kulikovskaya, Irina
    Nazimuddin, Farzana
    Zheng, Zhaohui
    Levine, Bruce L.
    Porter, David L.
    Lacey, Simon F.
    Melenhorst, Jan J.
    June, Carl H.
    Grupp, Stephan A.
    BLOOD, 2015, 126 (23)
  • [26] Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia
    Jacoby, Elad
    Bielorai, Bella
    Avigdor, Abraham
    Itzhaki, Orit
    Hutt, Daphna
    Nussboim, Vered
    Meir, Amilia
    Kubi, Adva
    Levy, Michal
    Zikich, Dragoslav
    Zeltzer, Li-at
    Brezinger, Karin
    Schachter, Jacob
    Nagler, Arnon
    Besser, Michal J.
    Toren, Amos
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (12) : 1485 - 1492
  • [27] Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
    Liu, Sining
    Zhang, Xinyue
    Dai, Haiping
    Cui, Qingya
    Cui, Wei
    Yin, Jia
    Li, Zheng
    Xue, Shengli
    Yang, Chunxiu
    Yang, Xiao
    Qiu, Huiying
    Miao, Miao
    Chen, Suning
    Jin, Zhengming
    Fu, Chengcheng
    Li, Caixia
    Sun, Aining
    Han, Yue
    Wang, Ying
    Yu, Lei
    Wu, Depei
    Tang, Xiaowen
    BLOOD, 2021, 138
  • [28] CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia
    Lorentzen, C. L.
    Straten, P. T.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2015, 82 (04) : 307 - 319
  • [29] Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
    Hanren Dai
    Zhiqiang Wu
    Hejin Jia
    Chuan Tong
    Yelei Guo
    Dongdong Ti
    Xiao Han
    Yang Liu
    Wenying Zhang
    Chunmeng Wang
    Yajing Zhang
    Meixia Chen
    Qingming Yang
    Yao Wang
    Weidong Han
    Journal of Hematology & Oncology, 13
  • [30] Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
    Roddie, Claire
    Dias, Juliana
    O'Reilly, Maeve A.
    Abbasian, Mahnaz
    Cadinanos-Garai, Amaia
    Vispute, Ketki
    Bosshard-Carter, Leticia
    Mitsikakou, Marina
    Mehra, Vedika
    Roddy, Harriet
    Hartley, John A.
    Spanswick, Victoria
    Lowe, Helen
    Popova, Bilyana
    Clifton-Hadley, Laura
    Wheeler, Graham
    Olejnik, Joanna
    Bloor, Adrian
    Irvine, David
    Wood, Leigh
    Marzolini, Maria A., V
    Domning, Sabine
    Farzaneh, Farzin
    Lowdell, Mark W.
    Linch, David C.
    Pule, Martin A.
    Peggs, Karl S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (30) : 3352 - +
12345